Blockchain & Fintech has the potential to disrupt and transform numerous industries. These technologies enable the trustless collaboration, reducing complexity and creating secure and immutable information. With the help of the blockchain and fintech, the financial industry has witnessed advanced innovations, larger investments and greater productivity.
As the era of personalized medicine is fast approaching, healthcare is becoming more personalized and tailored to the patient. Digital health platforms has helped converting medical data into a continuous, reliable and complete picture of the patient's health, and data analytics algorithms process information that is specific to individuals, leading to more personal and effective solutions.
MarketsandMarkets are proud to host its inaugural “Digital Transformation and Precision Medicine Virtual Conference” which will be held on 11th-12th June 2020. The conference will focus on the innovative and disruptive digital health technologies and futuristic business models transforming the precision medicine industry. The conference further aims in bringing experts from the academics, pharma, start-ups, hospitals and technology providers who will share their recent technological breakthroughs in personalized medicine.
Witness the major breakthroughs of microbiome, probiotics and prebiotics research along with their applications pertaining to challenges like medicinal data interpretation, investment and regulatory hurdles faced by the practitioners. The intersection between emerging technology and discovery with the context of consumer interest. Detect the non-identified dysbiosis, to discover the potential areas under study for investments in Gut and Skin microbiome and its role as a diagnostic tool of pharmaceutical discovery.
See the Post Show report of our inaugural event here
Due to growing concerns about COVID-19, the 3rd Annual MarketsandMarkets Next Gen IO Congress is going fully virtual this year. We are disappointed that we are not able to come together in person in June for this event, but we are so thrilled to see you on an online platform. We are working together to create a virtual conference that will be beneficial and engaging for speakers, attendees and sponsors/exhibitors.
See the Post Show report of our 2nd Annual here
Over the last decade, the field of cell therapy has rapidly grown, and it holds enormous promise for treating many diseases. In our conference of 2017, we assessed the specific risks and benefits of the cell culture and cell therapy bio-manufacturing for the cure of these diseases.
Due to growing concerns about COVID-19, the MarketsandMarkets World Pharma Logistics and Supply Chain Conference is going fully virtual this year. We are disappointed that we are not able to come together in person in June for this event, but we are so thrilled to see you on an online platform. We are working together to create a virtual conference that will be beneficial and engaging for speakers, attendees and sponsors/exhibitors.
Please write to firstname.lastname@example.org for questions regarding speaking, attending and sponsoring. We will keep you posted with the event flow soon. Keep checking our website.
While the viruses play a major role in molecular and cell biology to epidemiology, immunobiology and medical research, it has now become more crucial due to the global pandemic effect.
The revelation of immunization has prompted the near eradication of several disease and has tremendously affected wellbeing and health.
Ongoing advances in vaccine innovation coming from the application of genetic engineering like mRNA & DNA are now providing an opportunity to target new diseases.
However, even with novel platforms, COVID-19 vaccine development poses challenges. Debate continues over the best methodology — for instance, targeting the full-length protein or just the receptor-binding domain.
Protein-based drugs are a fast-growing class on the pharmaceutical market, with thousands of candidates in development. The most widely applied aspect of the protein engineering is antibody engineering. Bispecific and Monoclonal Abs have revolutionized the field of diagnosis and immunotherapy for the treatment of a variety of diseases.
New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.
MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases scheduled to be held on 9th -10th July 2020 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally-renowned speakers can describe how their analysis journeys have developed the response towards up to date challenges. The attending specialists and trade partners will offer an incredible networking expertise.
Harnessing data has become integral to any organization’s growth and development. The continuous evolution of Big Data technology has led to the growing use of AI, ML and cloud architecture. With newer trends emerging, it is essential to keep track of these and incorporate them into our data strategy. The Global Pandemic has also caused tech giants to invest in collecting, analysing and strategizing on transforming their businesses through digitization. To leverage the opportunities and address industry challenges, the masterclass focuses on building efficient data strategies, accelerating business values through data-driven transformation, developing a stable cloud computing architecture, using AI and ML effectively and overcoming data management challenges during COVID-19.
The complexity and immense omics data transform work into the big data age of biology and biomedicine. The recent advancement in sequencing technology has contributed to exponentiality in the amount of high-capacity data being generated. Life scientists fall into the flooding of big data from the omics experiment. The data integration is an effective method to solve the complex problem. These omics data hold the key to new research discoveries and are promising to revolutionize healthcare. Yet processing the data is the biggest challenge. Present methods are often too hard to use, and the research takes too long.
The world is going through a pandemic situation and the economy is crashing day by day. To revive the financial systems, the show must go on! Desperate times need desperate measures, the simple ways in which leaders can help their employees stay productive, focused, and psychologically healthy is by letting them work from home during the current scenario.
The technologies have given the instant access which can significantly blur the lines between the physical office and the place where work actually happens!
What is the future of technology in the Automotive industry? Automotive companies are embracing connected and smart technologies to offer safer and future-ready vehicles by investing in Advanced Driver Assistance Systems (ADAS). The battleground to win the customers is one of the driving forces for automotive manufacturers and OEMs to adopt the technology and lead the marketplace. However, the safety concerns and regulations around autonomous vehicles, communications systems, etc are limiting the acceptance of the technology.
The cytotoxic nature of HPAPIs presents significant handling challenges and thus requires heavy investments for implementing specialized containment facilities that facilitate the safety of employees from exposure. Owing to their target release characteristics, HPAPIs find major applications in target therapies for cancer.
One of the major challenges faced by the players in this market, especially CMOs that offer HPAPI manufacturing services, is the continual evolution of industry standards, technologies, and regulations.
MarketsandMarkets is proud to announce the 4th Annual High Potent Medicines Conference to be held on 21st - 22nd September 2020. This conference would address the challenges in the continual evolution of industry standards, technologies, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations, live case studies and breakthrough panel discussions.
Industrial revolution influences mission-critical applications in business processes and the manufacturing companies that take the risk and are early adopters of new technology will be rewarded for their progressive decision-making. Since, digitization helps to ensure product quality and safety, as well as faster service delivery, which goes a long way with customers. This has made the revolution the need of the hour!
The successful inaugural event of MarketsandMarkets Industry 4.0 Conference-Chicago, focused on the impact of IIOT and Cybersecurity, by addressing a series of application-based illustrations and discussions to map the future possibility of trends in the manufacturing world.
As per MarketsandMarkets research analysis, the global dPCR and qPCR is estimated to grow to USD 6,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use.